Centers for Medicare & Medicaid Services (CMS) Issue New ICD-10-PCS Code for ZOLL Medical's TherOx SSO2 Therapy
Retrieved on:
Thursday, July 14, 2022
Research, General Health, Professional Services, Pharmaceutical, Technology, Medical Devices, Hospitals, Science, Biotechnology, Insurance, FDA, Other Technology, Health, Health care, Ammonia, Data management, Life, Health information management, LAD, Solution, Asahi Kasei, Infarction, EMS, Muscle tissue, Atherosclerosis Risk in Communities, Patient, Supersaturation, Center, Institute for Community Studies, Mortality, Centers for Medicare & Medicaid Services, CPR, CMS, Diagnosis, STEMI, Cardiac muscle, Data collection, Medicare, Health, Angioplasty, Epidemiology, Atherosclerosis, FDA, Research, Hamad Medical Corporation, Hospital, Dialysis, Ventilation, Risk, Myocardial infarction, Sleep apnea, Classification, Pharmaceutical industry, Medical device
ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination and Maintenance Committee has issued a new ICD-10-PCS code for TherOx SuperSaturated Oxygen (SSO2) Therapy.
Key Points:
- ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination and Maintenance Committee has issued a new ICD-10-PCS code for TherOx SuperSaturated Oxygen (SSO2) Therapy.
- The new code (5A0222C), for cardiac intra-arterial use, is effective for hospital discharges beginning October 1, 2022.
- The code includes treatment of patients with left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attacks, which have higher mortality rates than other types of heart attacks.
- TherOx and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.